Fig. 1

FGFR Alterations in NMIBC and MIBC. A Mutation landscape of 58 significantly mutated genes defined by the TCGA publication [9] in 389 bladder cancer (BLCA) samples from the OMPU-NCC cohort. The patients were classified into pTa (n = 59), pT1 (n = 65), and ≥ pT2 (n = 265, MIBC: muscle-invasive bladder cancer). B Recurrent mutation rate of 58 significantly mutated genes according to pathological T stages. C Schematic of the FGFR3 fusions identified in our cohort. FGFR3-TACC3 fusions were found in 14 of 289 patients, and the most frequent pattern (7 of 11) is shown. NSD2 and SPON2 are newly identified fusion partners. D FGFR3 mRNA expression levels according to the FGFR3 alterations. The difference was assessed by the Mann–Whitney U test; p < 0.05*, p < 0.001**, p < 0.0001***. E, F Kaplan–Meier curves demonstrating progression-free survival (PFS) in non-muscle-invasive bladder cancer (NMIBC) (E) and overall survival (OS) in MIBC (F). A log-rank test was used to assess the survival difference between the two groups; p < 0.05*